Detail akcie Ligand Pharma online

Business Summary: Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Ligand Pharmaceuticals Inc revenues increased 68% to $208.4M. Net income increased from $27.1M to $79.7M. Revenues reflect Other segment increase from $1.9M to $59.2M, Filspari segment increase from $7.4M to $21M. Net income benefited from Other income, net decrease of 97% to $1.6M (expense), Impairment of Intangibles Excl Goodwill decrease from $26.5M (expense) to $0K.